+

WO2009043049A3 - Formules pharmaceutiques - Google Patents

Formules pharmaceutiques Download PDF

Info

Publication number
WO2009043049A3
WO2009043049A3 PCT/US2008/078193 US2008078193W WO2009043049A3 WO 2009043049 A3 WO2009043049 A3 WO 2009043049A3 US 2008078193 W US2008078193 W US 2008078193W WO 2009043049 A3 WO2009043049 A3 WO 2009043049A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulations
carnitine
creatine
creatinine
biologically active
Prior art date
Application number
PCT/US2008/078193
Other languages
English (en)
Other versions
WO2009043049A2 (fr
Inventor
Christopher James Sloey
Camille Vergara
Jason Ko
Tiansheng Li
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to CA2701032A priority Critical patent/CA2701032C/fr
Priority to ES08833819T priority patent/ES2750254T3/es
Priority to EP08833819.9A priority patent/EP2205280B1/fr
Priority to AU2008304111A priority patent/AU2008304111B2/en
Priority to US12/680,128 priority patent/US8383114B2/en
Publication of WO2009043049A2 publication Critical patent/WO2009043049A2/fr
Publication of WO2009043049A3 publication Critical patent/WO2009043049A3/fr
Priority to US13/742,818 priority patent/US9320797B2/en
Priority to US15/089,036 priority patent/US10653781B2/en
Priority to US16/878,385 priority patent/US20200276313A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur une formule pharmaceutique stable comprenant une protéine biologiquement active et un excipient sélectionné parmi la carnitine, la créatine ou la créatinine.
PCT/US2008/078193 2007-09-27 2008-09-29 Formules pharmaceutiques WO2009043049A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2701032A CA2701032C (fr) 2007-09-27 2008-09-29 Formules pharmaceutiques
ES08833819T ES2750254T3 (es) 2007-09-27 2008-09-29 Formulaciones farmacéuticas
EP08833819.9A EP2205280B1 (fr) 2007-09-27 2008-09-29 Formules pharmaceutiques
AU2008304111A AU2008304111B2 (en) 2007-09-27 2008-09-29 Pharmaceutical formulations
US12/680,128 US8383114B2 (en) 2007-09-27 2008-09-29 Pharmaceutical formulations
US13/742,818 US9320797B2 (en) 2007-09-27 2013-01-16 Pharmaceutical formulations
US15/089,036 US10653781B2 (en) 2007-09-27 2016-04-01 Pharmaceutical formulations
US16/878,385 US20200276313A1 (en) 2007-09-27 2020-05-19 Pharmaceutical Formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97578007P 2007-09-27 2007-09-27
US60/975,780 2007-09-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/680,128 A-371-Of-International US8383114B2 (en) 2007-09-27 2008-09-29 Pharmaceutical formulations
US13/742,818 Division US9320797B2 (en) 2007-09-27 2013-01-16 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
WO2009043049A2 WO2009043049A2 (fr) 2009-04-02
WO2009043049A3 true WO2009043049A3 (fr) 2010-03-04

Family

ID=40139180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/078193 WO2009043049A2 (fr) 2007-09-27 2008-09-29 Formules pharmaceutiques

Country Status (6)

Country Link
US (4) US8383114B2 (fr)
EP (1) EP2205280B1 (fr)
AU (1) AU2008304111B2 (fr)
CA (1) CA2701032C (fr)
ES (1) ES2750254T3 (fr)
WO (1) WO2009043049A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2701032C (fr) * 2007-09-27 2021-01-26 Amgen Inc. Formules pharmaceutiques
US8796206B2 (en) * 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
BRPI0916072A2 (pt) * 2008-11-17 2015-11-10 Genentech Inc "uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
US20130171128A1 (en) * 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP2598167B1 (fr) * 2010-07-30 2015-04-01 Arecor Limited Compositions aqueuses stabilisées d'anticorps
US9402919B2 (en) 2011-03-04 2016-08-02 Intrexon Corporation Vectors conditionally expressing protein
SG193963A1 (en) * 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity
AU2012243126A1 (en) * 2011-04-07 2013-10-17 Glaxosmithkline Llc Formulations with reduced viscosity
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014152511A1 (fr) 2013-03-15 2014-09-25 The Jackson Laboratory Procédés favorisant la cicatrisation des plaies et la croissance des poils
IL312865B1 (en) 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
CA2962768C (fr) 2014-10-01 2023-10-10 Alyssa M. Larson Formulations de polysaccharides et d'acides nucleiques contenant des agents reducteurs de viscosite
WO2016118707A1 (fr) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation de variants de charge dans une composition d'anticorps monoclonaux
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
EP3411401A1 (fr) 2016-02-03 2018-12-12 Oncobiologics, Inc. Formulations de tampon pour améliorer la stabilité d'anticorps
EP3624846B1 (fr) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. Formulations de protéines à haute concentration ayant une viscosité réduite incluant une mixture d'acide nicotinique et tryoptophane
KR20200119275A (ko) * 2018-02-09 2020-10-19 젠맵 에이/에스 Cd3 및 cd20에 대해 지정된 이중특이적 항체를 포함하는 제약 조성물 및 그의 용도
WO2019201904A1 (fr) * 2018-04-16 2019-10-24 Merck Patent Gmbh Réduction de la viscosité de formulations de protéines hautement concentrées
EP3817727A1 (fr) 2018-07-05 2021-05-12 Bayer Aktiengesellschaft Procédé pour la production de comprimés lyophilisés comprenant un anticorps du facteur xia anti-coagulation (fxia)
WO2021061944A1 (fr) * 2019-09-25 2021-04-01 The Regents Of The University Of California Créatine pour immunothérapie

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000397A1 (fr) * 1988-07-13 1990-01-25 Cetus Corporation Composition pharmaceutique pour interleukine-2 contenant des stabilisants physiologiquement compatibles
WO2001028360A1 (fr) * 1999-10-19 2001-04-26 Galactogen Products Ltd Produit alimentaire energetique
EP1188445A1 (fr) * 1999-06-24 2002-03-20 Ltt Institute Co., Ltd. Composition medicamenteuse contenant une superoxyde dismutase modifiee par lecithine
WO2007057748A2 (fr) * 2005-11-18 2007-05-24 Umberto Cornelli Utilisation du colostrum pour la prophylaxie des syndromes grippaux

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US7217689B1 (en) * 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
JP3053873B2 (ja) * 1994-08-12 2000-06-19 イムノメディクス，インコーポレイテッド Ｂ細胞リンパ腫細胞および白血病細胞に特異的な免疫結合体およびヒト化抗体
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
DE19715694B4 (de) * 1996-04-17 2006-01-19 Kansai Paint Co., Ltd., Amagasaki Verfahren zur Bildung eines mehrschichtigen Überzugs und nach dem Verfahren beschichteter Gegenstand
KR100643058B1 (ko) 1996-12-03 2006-11-13 아브게닉스, 인크. 복수의 Ｖн 및 Ｖк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2296770A1 (fr) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derives d'hormone de croissance et proteines associees
US6391633B1 (en) * 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6030086A (en) * 1998-03-02 2000-02-29 Becton, Dickinson And Company Flash tube reflector with arc guide
US6310078B1 (en) * 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
DK1088084T3 (da) 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-humant serumalbumin fusionsprotein
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
AU773891C (en) 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AR020848A1 (es) 1998-10-23 2002-05-29 Amgen Inc Metodos y composiciones para la prevencion y el tratamiento de anemia
JP4813660B2 (ja) * 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
EP1006184A1 (fr) * 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag Protéines interagissant avec le récepteur de IGF-1, gènes codant pour ces protéines et leurs utilisations
WO2000061637A1 (fr) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Anticorps du recepteur d'erythropoietine
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
AUPQ599700A0 (en) * 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DE60134003D1 (de) 2000-04-21 2008-06-26 Amgen Inc Verfahren und zusammensetzungen zur vermeidung und behandlung von anämie
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
MXPA03001451A (es) 2000-09-08 2004-12-13 Gryphon Therapeutics Inc Ligacion quimica pseudo nativa.
CA2430013C (fr) * 2000-11-30 2011-11-22 Medarex, Inc. Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
WO2002049673A2 (fr) 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugues d'erythropoietine
EE05724B1 (et) * 2001-01-05 2014-10-15 Pfizer Inc. Antikehad insuliinitaolise kasvufaktori I retseptorile
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
KR20040032094A (ko) 2001-04-04 2004-04-14 젠오디세 에리트로포이에틴 유전자의 신규한 폴리뉴클레오티드 및폴리펩티드
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
SI1385882T1 (sl) * 2001-05-11 2008-04-30 Amgen Inc Peptidi in sorodne molekule, ki se vežejo na tall-1
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
IL160358A0 (en) * 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
WO2003025020A1 (fr) * 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AU2002351746A1 (en) 2001-12-21 2003-07-15 Maxygen Aps Erythropoietin conjugates
EP1461359B1 (fr) 2002-01-18 2007-03-21 Pierre Fabre Medicament Anticorps anti-igf-ir et leurs applications
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP1470232A1 (fr) * 2002-01-31 2004-10-27 Oxford Biomedica (UK) Limited Vecteur d'expression de l'erythropoietine physiologiquement regule, destine au traitement de l'anemie
GB0202252D0 (en) * 2002-01-31 2002-03-20 Oxford Biomedica Ltd Anemia
DE60220451T2 (de) * 2002-03-26 2008-01-24 Lek Pharmaceutical And Chemical Co. D.D. Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
CN1326879C (zh) * 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
WO2003084477A2 (fr) 2002-03-29 2003-10-16 Centocor, Inc. Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
GB2403476A (en) 2002-05-13 2005-01-05 Modigenetech Ltd CTP-extended erythropoietin
NZ554740A (en) * 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP1575499A2 (fr) 2002-06-28 2005-09-21 Centocor, Inc. Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees
JP2006504406A (ja) 2002-06-28 2006-02-09 セントカー・インコーポレーテツド 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用
WO2004009627A1 (fr) 2002-07-19 2004-01-29 Cangene Corporation Composes erythropoietiques pegyles
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
NZ566539A (en) * 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
CA2495242A1 (fr) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Polypeptides-has, notamment, erythropoietine-has ayant subi une acylation
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20040071694A1 (en) * 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
TWI320716B (en) 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
US7335743B2 (en) * 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
DK1581649T3 (da) 2002-12-20 2011-05-02 Amgen Inc Myostatininhiberende bindemidler
US7195839B2 (en) 2003-02-11 2007-03-27 Eveready Battery Company, Inc. Battery cell with improved pressure relief vent
EP1603948A1 (fr) * 2003-03-14 2005-12-14 Pharmacia Corporation Anticorps specifiques du recepteur d'igf-i pour le traitement de cancers
US7378503B2 (en) * 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
CN102258464A (zh) * 2003-04-04 2011-11-30 健泰科生物技术公司 高浓度抗体和蛋白制剂
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
WO2005016970A2 (fr) 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2525464A1 (fr) 2003-05-12 2004-11-25 Qun Yin Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations
DK1625156T3 (da) 2003-05-12 2013-01-07 Affymax Inc Peptider, der bindes til erythropoietinreceptoren
EA010095B1 (ru) * 2003-05-12 2008-06-30 Афимакс, Инк. Новые пептиды, которые связываются с рецептором эритропоэтина
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
KR20060032140A (ko) 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
WO2005001136A1 (fr) 2003-06-04 2005-01-06 Irm Llc Methodes et compositions pour la modulation de l'expression de l'erythropoietine
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
US7601818B2 (en) * 2003-07-15 2009-10-13 Amgen, Inc. Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
AR042955A1 (es) * 2003-07-18 2005-07-13 Amgen Inc Agentes de union especifica al factor de crecimiento de hepatocitos
US20050019914A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005021579A2 (fr) 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Peptides mimetiques epo et proteines de fusion
BRPI0409650A (pt) 2003-09-09 2006-04-25 Warren Pharmaceuticals Inc métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
WO2005081687A2 (fr) 2003-09-30 2005-09-09 Centocor, Inc. Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes
CN1886426A (zh) 2003-11-07 2006-12-27 伊姆尼斯公司 结合白细胞介素－4受体的抗体
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
NZ547168A (en) 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
WO2005058967A2 (fr) 2003-12-16 2005-06-30 Pierre Fabre Medicament Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
EP1548031A1 (fr) 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Erythropoietin identique à la nature
EP1699920A4 (fr) * 2003-12-31 2008-05-28 Centocor Inc Nouvelles proteines recombinees avec thiol libre n-terminal
PT1699821E (pt) * 2003-12-31 2012-08-23 Merck Patent Gmbh Proteína de fusão fc-eritropoietina com farmacocinética melhorada
US7423139B2 (en) * 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20050187158A1 (en) 2004-01-22 2005-08-25 Ranby Mats G. Pharmaceutical composition
WO2005084711A1 (fr) 2004-03-02 2005-09-15 Chengdu Institute Of Biological Products Erythropoietine recombinante pegylee a activite in vivo
TW200603818A (en) 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
US20050227289A1 (en) * 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
JP2008508854A (ja) 2004-04-23 2008-03-27 ケンブリッジ アンティボディー テクノロジー リミテッド エリスロポイエチンタンパク質変異体
WO2006002646A2 (fr) 2004-07-07 2006-01-12 H. Lundbeck A/S Nouvelle erythropoietine carbamylee et son procede de production
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US20060073563A1 (en) 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
WO2006050959A2 (fr) 2004-11-10 2006-05-18 Aplagen Gmbh Molecules favorisant l'hematopoiese
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1841455A1 (fr) 2005-01-24 2007-10-10 Amgen Inc. Anticorps anti-amyloide humanise
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
WO2007000328A1 (fr) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
NZ604090A (en) 2005-07-18 2014-07-25 Amgen Inc Human anti-b7rp1 neutralizing antibodies
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
CA2701032C (fr) * 2007-09-27 2021-01-26 Amgen Inc. Formules pharmaceutiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000397A1 (fr) * 1988-07-13 1990-01-25 Cetus Corporation Composition pharmaceutique pour interleukine-2 contenant des stabilisants physiologiquement compatibles
EP1188445A1 (fr) * 1999-06-24 2002-03-20 Ltt Institute Co., Ltd. Composition medicamenteuse contenant une superoxyde dismutase modifiee par lecithine
WO2001028360A1 (fr) * 1999-10-19 2001-04-26 Galactogen Products Ltd Produit alimentaire energetique
WO2007057748A2 (fr) * 2005-11-18 2007-05-24 Umberto Cornelli Utilisation du colostrum pour la prophylaxie des syndromes grippaux

Also Published As

Publication number Publication date
US20170049895A1 (en) 2017-02-23
US20100297106A1 (en) 2010-11-25
AU2008304111A1 (en) 2009-04-02
US8383114B2 (en) 2013-02-26
AU2008304111B2 (en) 2014-04-24
EP2205280B1 (fr) 2019-09-04
CA2701032C (fr) 2021-01-26
EP2205280A2 (fr) 2010-07-14
WO2009043049A2 (fr) 2009-04-02
ES2750254T3 (es) 2020-03-25
US9320797B2 (en) 2016-04-26
US20130121990A1 (en) 2013-05-16
CA2701032A1 (fr) 2009-04-02
US20200276313A1 (en) 2020-09-03
US10653781B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
WO2009043049A3 (fr) Formules pharmaceutiques
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
WO2005021022A3 (fr) Formulations de peptides stables
WO2006135933A3 (fr) Forme posologique pharmaceutique unitaire
NO20083973L (no) Farmasøytiske sammensetninger omfattende metylnaltrekson, kalsiumetylendiamintrieddiksyre og glycin.
IL185390A (en) A solid dosage form
WO2011109415A3 (fr) Réduction de la viscosité de formulations pharmaceutiques
ZA200709921B (en) Biologically active formulation based on cyclodextrin supramolecular complexes
DK2985026T3 (da) Farmaceutiske leveringssystemer til hydrofobe lægemidler og sammensætninger dermed
NO20054555D0 (no) Farmasoytiske preparater som omfatter syrestabilisert insulin
WO2008128775A3 (fr) Composition pharmaceutique stabilisée contenant de la prégabaline
WO2007016284A3 (fr) Preparations/compositions pharmaceutiques de guanfacine destinees a l'administration d'une dose quotidienne unique
EP2045253A4 (fr) DÉRIVÉ D'ACIDE alpha-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
EP1985287A3 (fr) Complexe d'excipient pharmaceutique
EP1831240B8 (fr) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones et preparations pharmaceutiques contenant ces derniers
WO2005046637A3 (fr) Formulations pharmaceutiques utilisant des sphingolipides a chaine courte et leur application
WO2007086911A3 (fr) Formulations nanoparticulaires stables
GB0617875D0 (en) Controlled delivery creatine formulations and method of using the same
PT1742927E (pt) Derivados do ácido butanóico, processos para a sua preparação, composições farmacêuticas que os contêm, e suas aplicações terapêuticas
ZA200804086B (en) Stable pharmaceutical formulations containing escitalo-pram and bupropion
WO2005051353A3 (fr) Formulations pharmaceutiques
WO2007071721A3 (fr) Extrait de gingembre pour inhiber des transporteurs de medicament humains

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08833819

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008304111

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2701032

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008833819

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008304111

Country of ref document: AU

Date of ref document: 20080929

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12680128

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载